Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2016/1492743 http://scihub22266oqcxt.onion/10.1155/2016/1492743 C4749773!4749773!26942026     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Case+Rep+Nephrol 2016 ; 2016 (ä): ä Nephropedia Template TP {{tp|p=26942026|t=2016. Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease |pdf=|usr=}}{{26942026}} gab.com Text Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease JO: Case Rep Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26942026 #FOAvip No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and patients require renal replacement therapy early in life. Microhematuria and subsequently proteinuria are hallmarks of kidney involvement, which are due to primary basement membrane alterations that mainly cause endothelial thrombosis and podocyte contraction and ulterior irreversible detachment. Commonly drug-based approaches include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are employed to reduce proteinuria and thus retard kidney disease progression and cardiovascular morbidity and mortality. However, as any hereditary disease, it is expressed as early as in the intrauterine life, and usually an index case is helpful to detect family-related cases. As no specific treatment exists, pathophysiologically based approaches are useful. The present case illustrates the reduction rate of urinary podocyte loss and proteinuria after amiloride administration and suggests the molecular pathways involved in Alport renal disease. Finally, podocyturia rather than proteinuria should be considered as an earlier biomarker of kidney involvement and disease progression in Alport disease. Twit Text FOAVip Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease ????Case Rep Nephrol http://www.kidney.de/pget.php?&tw=1&pmid=26942026 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26942026 #FOAvip English Wikipedia <ref>{{Cite pmid|26942026}}</ref> Podocyturia: A Clue for the Rational Use of Amiloride in Alport Renal Disease #MMPMID26942026 Trimarchi H; Canzonieri R; Muryan A; Schiel A; Araoz A; Paulero M; Andrews J; Rengel T; Forrester M; Lombi F; Pomeranz V; Iriarte R; Zotta E Case Rep Nephrol 2016[]; 2016 (ä): ä PMID26942026show ga No specific or efficient treatment exists for Alport syndrome, an X-linked hereditary disease caused by mutations in collagen type IV, a crucial component of the glomerular basement membrane. Kidney failure is usually a major complication of the disease, and patients require renal replacement therapy early in life. Microhematuria and subsequently proteinuria are hallmarks of kidney involvement, which are due to primary basement membrane alterations that mainly cause endothelial thrombosis and podocyte contraction and ulterior irreversible detachment. Commonly drug-based approaches include angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, which are employed to reduce proteinuria and thus retard kidney disease progression and cardiovascular morbidity and mortality. However, as any hereditary disease, it is expressed as early as in the intrauterine life, and usually an index case is helpful to detect family-related cases. As no specific treatment exists, pathophysiologically based approaches are useful. The present case illustrates the reduction rate of urinary podocyte loss and proteinuria after amiloride administration and suggests the molecular pathways involved in Alport renal disease. Finally, podocyturia rather than proteinuria should be considered as an earlier biomarker of kidney involvement and disease progression in Alport disease. äPodocyturia: A Clue for the Rational Use of Amiloride in Alport Renal (epmc).pdf DeepDyve Pubget Overpricing